Comments
Global pharma major Lupin has received approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application for Varenicline Tablets, 0.5 mg and 1 mg, for use as an aid to smoking cessation treatment.
The tablet is a generic equivalent of Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. The product will be manufactured at the company’s Pithampur facility in India.
In addition, the company claimed in its regulatory filing that it has invested 7.9 per cent of its revenue in research and development in FY23.
Lupin stock inches up by 0.19 per cent on the NSE, trading at ₹1,260.55.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.